The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients.

The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new ...

Listed Funds Trust - Overlay Shares Small Cap Equity ETF (OVS) Declares $0.26 Dividend July 05, 2023 — 12:35 am EDT Written by George Maybach for Fintel -> ...

Despite a weaker-than-expected start, OVS SpA (FRA:0OV1) leverages strategic acquisitions and favorable market conditions to drive future growth.

Quarterly Performance Highlights OVS reported Q1 2025 net sales of €354.4 million, representing a 0.6% increase compared to the same period in 2024.

OVS had in June forecast year-on-year growth for 2023 without providing detailed estimates. The group said it plans to purchase an additional 20 million euros worth of its own shares as part of a ...

OVS S.p.A. ( ($IT:OVS) ) has provided an update. OVS S.p.A. announced the purchase of 20,791 of its own shares on Euronext Milan, representing ...

OVS S.p.A. quarterly income statement. View OVS.IT financial statements in full, including balance sheets and ratios.

OVS reported Q1 2025 net sales of €354.4 million, representing a 0.6% increase compared to the same period in 2024. This growth was achieved despite what the company described as "a market still held ...